Company profile
CDMO Pharmaceutical Contract Manufacturing - Quay Pharma
CDMO Pharmaceutical Contract Manufacturing , CDMO, Pharmaceutical Contract Manufacturing , World-leading pharmaceutical CDMO, experts in formulation development of innovative new entities for biotech companies, globally.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
AA | Transaction MzQzODMwNTM5OGFkaXF6a2N4 | Paper/PDF filed
Published 10 Oct 2024 06:26
Company registered at Companies House
1 May 2021 to 30 Apr 2023
To develop novel, industry-relevant methods of manufacturing enabled nanoparticle formulations of poorly soluble drugs to improve and enhance delivery of the drug to the gastro-intestinal tract.
1 Jan 2021 to 31 Mar 2024
To find alternative and more efficient processes to stabilise bacteria following growth and harvesting of the bacterial cells, leading to a less destructive and more cost-effective method of producing large scale bacteria for the production of live biotherapeutic products.
1 Oct 2018 to 30 Sep 2021
Though the monoclonal antibody (mAb), infliximab, is considered a gold-standard treatment for the 300,000 patients in the UK with inflammatory bowel disease (IBD), the compound can only be administered through an inconvenient and often painful injection. In doing so, only less than 1% of the drug reaches the site of disease, limiting the efficacy of the t...
1 Oct 2015 to 31 Mar 2019
Awaiting Public Project Summary
1 Oct 2012 to 31 Jul 2015
To develop a new dosage form technology platform for the administration of oral medicines for geriatric and paediatric patients.
